Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BioDelivery Sciences International, Inc. stock logo
BDSI
BioDelivery Sciences International
$5.59
$5.58
$2.50
$5.62
$577.05M0.563.34 million shs2.09 million shs
BELLUS Health Inc. stock logo
BLU
BELLUS Health
$14.74
$14.62
$6.38
$14.76
$1.87B0.193.08 million shs3.45 million shs
Hookipa Pharma Inc stock logo
HOOK
Hookipa Pharma
$0.83
-5.7%
$0.78
$0.41
$2.05
$81.83M0.92743,259 shs843,695 shs
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
$7.65
+4.7%
$6.10
$2.86
$7.79
$324.51M1.82167,790 shs347,559 shs
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BioDelivery Sciences International, Inc. stock logo
BDSI
BioDelivery Sciences International
0.00%0.00%0.00%0.00%0.00%
BELLUS Health Inc. stock logo
BLU
BELLUS Health
0.00%0.00%0.00%0.00%+1.73%
Hookipa Pharma Inc stock logo
HOOK
Hookipa Pharma
-5.36%-6.45%+16.86%+31.39%-47.29%
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
+0.69%+2.24%+8.62%+36.38%+11.60%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
BioDelivery Sciences International, Inc. stock logo
BDSI
BioDelivery Sciences International
N/AN/AN/AN/AN/AN/AN/AN/A
BELLUS Health Inc. stock logo
BLU
BELLUS Health
N/AN/AN/AN/AN/AN/AN/AN/A
Hookipa Pharma Inc stock logo
HOOK
Hookipa Pharma
2.9972 of 5 stars
3.53.00.00.02.91.71.3
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
4.2196 of 5 stars
3.52.00.04.72.52.50.6

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
BioDelivery Sciences International, Inc. stock logo
BDSI
BioDelivery Sciences International
N/AN/AN/AN/A
BELLUS Health Inc. stock logo
BLU
BELLUS Health
N/AN/AN/AN/A
Hookipa Pharma Inc stock logo
HOOK
Hookipa Pharma
3.00
Buy$4.67464.29% Upside
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
3.00
Buy$11.2547.06% Upside

Current Analyst Ratings

Latest VRCA, HOOK, BLU, and BDSI Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/26/2024
Hookipa Pharma Inc stock logo
HOOK
Hookipa Pharma
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$6.50 ➝ $5.00
4/10/2024
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$8.00
3/25/2024
Hookipa Pharma Inc stock logo
HOOK
Hookipa Pharma
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$5.00
3/25/2024
Hookipa Pharma Inc stock logo
HOOK
Hookipa Pharma
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$6.50
3/1/2024
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$12.00 ➝ $13.00
3/1/2024
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$8.00
(Data available from 5/7/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
BioDelivery Sciences International, Inc. stock logo
BDSI
BioDelivery Sciences International
$166.70M3.46$0.36 per share15.42$1.90 per share2.94
BELLUS Health Inc. stock logo
BLU
BELLUS Health
$15K124,613.93N/AN/A$3.09 per share4.77
Hookipa Pharma Inc stock logo
HOOK
Hookipa Pharma
$20.13M4.07N/AN/A$0.91 per share0.91
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
$5.12M63.38N/AN/A$0.47 per share16.28

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
BioDelivery Sciences International, Inc. stock logo
BDSI
BioDelivery Sciences International
$84.86M$0.836.748.47N/A50.90%21.25%10.56%N/A
BELLUS Health Inc. stock logo
BLU
BELLUS Health
-$76.08M-$0.72N/AN/AN/A-578,586.63%-24.27%-23.14%N/A
Hookipa Pharma Inc stock logo
HOOK
Hookipa Pharma
-$81.58M-$0.88N/AN/AN/A-405.28%-72.30%-40.51%5/9/2024 (Estimated)
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
-$67M-$1.46N/AN/AN/A-1,307.47%-119.46%-70.35%5/14/2024 (Estimated)

Latest VRCA, HOOK, BLU, and BDSI Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
3/22/2024Q4 2023
Hookipa Pharma Inc stock logo
HOOK
Hookipa Pharma
-$0.20-$0.11+$0.09N/A$3.60 million$7.41 million
2/29/2024Q4 2023
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
-$0.47-$0.48-$0.01-$0.43$1.10 million$1.99 million    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
BioDelivery Sciences International, Inc. stock logo
BDSI
BioDelivery Sciences International
N/AN/AN/AN/AN/A
BELLUS Health Inc. stock logo
BLU
BELLUS Health
N/AN/AN/AN/AN/A
Hookipa Pharma Inc stock logo
HOOK
Hookipa Pharma
N/AN/AN/AN/AN/A
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
BioDelivery Sciences International, Inc. stock logo
BDSI
BioDelivery Sciences International
0.29
2.45
2.17
BELLUS Health Inc. stock logo
BLU
BELLUS Health
N/A
33.42
33.42
Hookipa Pharma Inc stock logo
HOOK
Hookipa Pharma
N/A
3.50
3.50
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
2.22
4.55
4.49

Ownership

Institutional Ownership

CompanyInstitutional Ownership
BioDelivery Sciences International, Inc. stock logo
BDSI
BioDelivery Sciences International
64.40%
BELLUS Health Inc. stock logo
BLU
BELLUS Health
90.37%
Hookipa Pharma Inc stock logo
HOOK
Hookipa Pharma
63.88%
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
42.45%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
BioDelivery Sciences International, Inc. stock logo
BDSI
BioDelivery Sciences International
200103.23 million92.93 millionOptionable
BELLUS Health Inc. stock logo
BLU
BELLUS Health
74126.81 million96.16 millionNot Optionable
Hookipa Pharma Inc stock logo
HOOK
Hookipa Pharma
5698.95 million94.40 millionOptionable
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
10042.42 million24.35 millionOptionable

VRCA, HOOK, BLU, and BDSI Headlines

SourceHeadline
Verrica Pharmaceuticals (VRCA) Moves 7.4% Higher: Will This Strength Last?Verrica Pharmaceuticals (VRCA) Moves 7.4% Higher: Will This Strength Last?
zacks.com - May 6 at 7:36 AM
VRCA Verrica Pharmaceuticals Inc.VRCA Verrica Pharmaceuticals Inc.
seekingalpha.com - May 3 at 11:22 PM
Verrica Pharmaceuticals Inc (VRCA)Verrica Pharmaceuticals Inc (VRCA)
investing.com - April 19 at 7:13 PM
Needham & Company LLC Reiterates "Buy" Rating for Verrica Pharmaceuticals (NASDAQ:VRCA)Needham & Company LLC Reiterates "Buy" Rating for Verrica Pharmaceuticals (NASDAQ:VRCA)
marketbeat.com - April 10 at 8:24 AM
Verrica Pharmaceuticals to Spotlight Innovations at Needham Healthcare ConferenceVerrica Pharmaceuticals to Spotlight Innovations at Needham Healthcare Conference
msn.com - April 4 at 11:15 AM
Strong week for Verrica Pharmaceuticals (NASDAQ:VRCA) shareholders doesnt alleviate pain of three-year lossStrong week for Verrica Pharmaceuticals (NASDAQ:VRCA) shareholders doesn't alleviate pain of three-year loss
finance.yahoo.com - April 3 at 8:23 AM
Verrica Pharmaceuticals Announces Presentation at the 23rd Annual Needham Virtual Healthcare ConferenceVerrica Pharmaceuticals Announces Presentation at the 23rd Annual Needham Virtual Healthcare Conference
globenewswire.com - April 2 at 7:30 AM
Verrica Pharmaceuticals Secures Key FDA Designation for YCANTH, Enhancing Market ProtectionVerrica Pharmaceuticals Secures Key FDA Designation for YCANTH, Enhancing Market Protection
msn.com - March 31 at 11:37 AM
Verrica Pharmaceuticals Inc.: Verrica Pharmaceuticals Announces that YCANTH Receives New Chemical Entity Status and Orange Book Listing from the FDAVerrica Pharmaceuticals Inc.: Verrica Pharmaceuticals Announces that YCANTH Receives New Chemical Entity Status and Orange Book Listing from the FDA
finanznachrichten.de - March 28 at 3:45 PM
Verrica Pharma gains as FDA lists Ycanth in Orange BookVerrica Pharma gains as FDA lists Ycanth in Orange Book
msn.com - March 27 at 3:42 AM
Verrica Pharmaceuticals: YCANTH Granted NCE Status By FDA - Quick FactsVerrica Pharmaceuticals: YCANTH Granted NCE Status By FDA - Quick Facts
markets.businessinsider.com - March 26 at 8:15 AM
Verrica Pharmaceuticals Announces that YCANTH™ Receives New Chemical Entity Status and Orange Book Listing from the FDAVerrica Pharmaceuticals Announces that YCANTH™ Receives New Chemical Entity Status and Orange Book Listing from the FDA
globenewswire.com - March 26 at 7:30 AM
Verrica Pharmaceuticals Set to Illuminate TD Cowen Healthcare Conference with Fireside ChatVerrica Pharmaceuticals Set to Illuminate TD Cowen Healthcare Conference with Fireside Chat
msn.com - March 3 at 10:22 PM
Verrica Pharmaceuticals Full Year 2023 Earnings: Revenues Beat Expectations, EPS In LineVerrica Pharmaceuticals Full Year 2023 Earnings: Revenues Beat Expectations, EPS In Line
finance.yahoo.com - March 2 at 10:39 AM
When Will Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Become Profitable?When Will Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Become Profitable?
finance.yahoo.com - March 2 at 10:39 AM
Verrica Pharmaceuticals Inc.: Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial ResultsVerrica Pharmaceuticals Inc.: Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results
finanznachrichten.de - March 1 at 11:46 PM
Verrica Pharmaceuticals Outperforms with YCANTH Sales, Promising Outlook Spurs Buy RatingVerrica Pharmaceuticals Outperforms with YCANTH Sales, Promising Outlook Spurs Buy Rating
markets.businessinsider.com - March 1 at 6:46 PM
Buy Rating Affirmed for Verrica Pharmaceuticals Following Strong Ycanth Launch and Strategic Market ExpansionBuy Rating Affirmed for Verrica Pharmaceuticals Following Strong Ycanth Launch and Strategic Market Expansion
markets.businessinsider.com - March 1 at 6:46 PM
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Q4 2023 Earnings Call TranscriptVerrica Pharmaceuticals Inc. (NASDAQ:VRCA) Q4 2023 Earnings Call Transcript
finance.yahoo.com - March 1 at 1:45 PM
Buy Rating Affirmed for Verrica Pharmaceuticals Amidst Promising Ycanth Launch and Market AcceptanceBuy Rating Affirmed for Verrica Pharmaceuticals Amidst Promising Ycanth Launch and Market Acceptance
markets.businessinsider.com - February 29 at 10:09 PM
Verrica Pharmaceuticals Inc (VRCA) Reports Fourth Quarter and Full-Year 2023 Financial ResultsVerrica Pharmaceuticals Inc (VRCA) Reports Fourth Quarter and Full-Year 2023 Financial Results
finance.yahoo.com - February 29 at 12:07 PM
Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial ResultsVerrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results
globenewswire.com - February 29 at 7:30 AM
Earnings Outlook For Verrica PharmaceuticalsEarnings Outlook For Verrica Pharmaceuticals
benzinga.com - February 28 at 6:01 PM
Verrica Pharmaceuticals Announces Participation in the TD Cowen 44th Annual Healthcare ConferenceVerrica Pharmaceuticals Announces Participation in the TD Cowen 44th Annual Healthcare Conference
globenewswire.com - February 27 at 7:30 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

BioDelivery Sciences International logo

BioDelivery Sciences International

NASDAQ:BDSI
BioDelivery Sciences International, Inc., a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products for chronic conditions in the United States and internationally. The company provides its products based on its patented BioErodible MucoAdhesive drug-delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug delivery technologies. It offers BELBUCA, a buprenorphine buccal film for the treatment of chronic pain; and Symproic, a peripherally acting mu-opioid receptor antagonist for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent opioid dosage escalation. The company also provides ELYXYB, a celecoxib oral solution for the treatment of migraine with or without aura in adults; and ONSOLIS, a fentanyl buccal soluble film for the management of breakthrough pain in cancer patients. BioDelivery Sciences International, Inc. was incorporated in 1997 and is headquartered in Raleigh, North Carolina. As of March 18, 2022, BioDelivery Sciences International, Inc. operates as a subsidiary of Collegium Pharmaceutical, Inc.
BELLUS Health logo

BELLUS Health

NASDAQ:BLU
BELLUS Health Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. BELLUS Health Inc. was incorporated in 1993 and is based in Laval, Canada. As of June 28, 2023, BELLUS Health Inc. operates as a subsidiary of GSK plc.
Hookipa Pharma logo

Hookipa Pharma

NASDAQ:HOOK
HOOKIPA Pharma Inc., a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in preclinical studies for the treatment of human papillomavirus-positive cancers. The company has a collaboration with Gilead Sciences, Inc. to develop arenavirus based therapeutics to treat hepatitis B virus and human immunodeficiency virus infections. HOOKIPA Pharma Inc. was founded in 2011 and is headquartered in New York, New York.
Verrica Pharmaceuticals logo

Verrica Pharmaceuticals

NASDAQ:VRCA
Verrica Pharmaceuticals Inc., a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts. The company also develops VP-315, an oncolytic peptide-based injectable therapy, which is in phase II clinical trial for the treatment of dermatology oncologic conditions which includes basal cell carcinoma; and VP-103, a cantharidin-based product candidate for the treatment of plantar warts and is in phase II clinical trial. In addition, it offers YCANTH for the treatment of molluscum contagiosum. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for dermatological oncology indications, such as non-metastatic melanoma and non-metastatic merkel cell carcinoma. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.